Dendrite Clinical Systems is delighted to report that our Managing Director, Dr Peter Walton, has published a chapter discussing the value of clinical registries in new publication on Laparoscopic Sleeve Gastrectomy (LSG). In his Chapter, Dr Peter Walton outlines value of national bariatric registries and their capability to deliver evidence on a global basis, as well as providing some practical perspectives on best practice when setting out to start a national registry and how to keep a good registry going.
Dendrite Clinical Systems and the Institute for Health Research (IGES) in Berlin, Germany, have initiated the Outpatient Treatment of COVID-19 Infections (ABC-19) study, to record data on the treatment of COVID-19 patients and discover more about the outpatient course of the disease, the individual risk factors of patients that contribute to severe COVID-19 courses and the procedures of general practitioners (GPs).
Researchers at the University College London and University College London Hospitals NHS Foundation Trust), London, UK, have reported that the vast majority of participants with new onset loss of smell were positive for COVID19, and this acute loss of sense of smell needs to be considered globally as a criterion for self-isolation, testing and contact tracing in order to contain the spread of COVID-19.
Dendrite Clinical Systems’ innovative “Intellect Web” software has been chosen by an international group of 17 leading diabetes experts from the multidisciplinary Diabetes Surgery Summit (DSS), as the platform on which the CoviDiab project will establish a Global Registry to collect new cases of diabetes in patients with COVID-19.
Two distinguished members join Dendrite’s Scientific Advisory Board
Dendrite Clinical Systems has announced the appointment of two members to the company’s newly established Scientific Advisory Board - Sir Bruce Keogh (KBE FMedSci FRCS FRCP) and Professor Anthony Goldstone (CBE MA (Oxon) FRCP FRCPE FRCPath). The Scientific Advisory Board has been created to provide unique advice and guidance to Dendrite’s management team by taking an objective look at our activities and sharing with us their experience and knowledge. This includes evaluating the scientific merit of projects, assessing progress and offering strategic input on the company’s priorities.
“We are delighted to welcome two illustrious members to our new Scientific Advisory Board, both of whom have unparallelled experience in the international healthcare sector,” said Dr Peter Walton, Dendrite’s managing Director. “Their expertise and knowledge will provide us with valuable insights into how we can enhance and improve our expanding software portfolio, as well as increase awareness of our company globally.”
Sir Bruce has had a distinguished international career as a cardiac surgeon. He developed a longstanding interest in clinical outcomes from working closely with Dendrite to establish a national database for adult cardiac surgery early in his surgical career.
He subsequently became chair of Cardiac Surgery at University College London and Director of Surgery at the Heart Hospital, before being appointed Medical Director of the National Health Service and Director General in the Department of Health (DoH), a role that later transferred to NHS England. During this period (2007-18) as the most senior doctor in the NHS he was had particular responsibility for the development and implementation clinical policy and strategy across the health service in England.
In the DoH, he was the Government sponsor for NICE, the Healthcare Commission and the National Patient Safety Agency. He has served on several boards including NHS England. He is currently Chair of the Birmingham Women’s and Children’s NHS Foundation Trust, he was knighted for Services to Medicine in 2003.
Professor Goldstone is a senior haematology specialist with over 35 years’ experience of working in the NHS. He was appointed as a Consultant at University College Hospital (UCH) in 1976 and initiated the first stages of what became the biggest Adult Haematology unit in the UK. Professor Goldstone is a former Medical Director of University College London Hospital, former President of the British Society of Haematology and former Chair of the European Society for Blood and Marrow Transplantation Lymphoma Group.
He specialises in adult haematology and haematological malignancy, adult leukaemia, lymphoma (Hodgkin's and Non-Hodgkin's Lymphoma) and myeloma and other non-malignant haematological conditions. The founder of the stem cell transplant unit at UCH, Professor Goldstone is a renowned pioneer in haematological stem cell transplantation. A Principal Investigator on many leukaemia trials in the UK and internationally, he is strong advocate of evidence-based medicine and believes registries now stand alongside randomised clinical trials as real-world evidence.
Professor Goldstone, a former Director of the North London Cancer Network, has published over 360 peer-reviewed papers in haematology and has authored three books. He was awarded a CBE June 2008 for Services to Medicine.
